Back to search
FDAFDA · Food and drugs·Recall number D-1221-2014

Magic Slim capsules (Ling Zhi, Ebony, Fox-nut, Tuckahoe, Seman Pruni, Dioscoreae, Wheat Germ, Nature Substance), 60-count bottles.

Published April 16, 2014 · Recall initiated: December 10, 2013

Summary

FDA records drug Class I recall D-1221-2014, published April 16, 2014 and initiated December 10, 2013. Recalling firm: Slim Beauty USA; Status: Terminated; Reported quantity: 2 bottles; Lot: No lot code information or exp date on packaging. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Marketed Without An Approved NDA/ANDA: The product contains undeclared sibutramine and phenolphthalein. Marketed Without An Approved NDA/ANDA: The product contains undeclared sibutramine and phenolphthalein. Sibutramine and phenolphthalein are not currently marketed in the United States, making this product an unapproved new drug.

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Slim Beauty USA
Distributor
Nationwide
Lot
No lot code information or exp date on packaging.
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Magic Slim capsules (Ling Zhi, Ebony, Fox-nut, Tuckahoe, Seman Pruni, Dioscoreae, Wheat Germ, Nature Substance), 60-count bottles. recalled?

Yes. FDA published recall D-1221-2014 on April 16, 2014. Reported hazard: Marketed Without An Approved NDA/ANDA: The product contains undeclared sibutramine and phenolphthalein. Marketed Without An Approved NDA/ANDA: The product contains undeclared sibutramine and phenolphthalein. Sibutramine and phenolphthalein are not currently marketed in the United States, making this product an unapproved new drug.

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail